Amylyx Pharmaceuticals co-CEOs Justin Klee (L) and Josh Cohen (Amylyx)
May 12, 2023 10:48 AM EDTUpdated 11:27 AM
R&D

Amy­lyx's Re­lyvrio pulls in $71M in rev­enue

Tyler Patchen

News Reporter

Amy­lyx’s ALS drug Re­lyvrio brought in $71.4 mil­lion in rev­enue in the first quar­ter of the year, far sur­pass­ing ex­pec­ta­tions for a CNS ther­a­py ap­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times